INFLUENCE OF ANTICOAGULANT THERAPY ON THE COAGULATION PROFILE OF PATIENTS WITH CORONAVIRUS INFECTION (COVID-19)
*Giyasova Masuda Giyasovna, Shamsutdinova Maksuda Ilyasovna, Yunusov Asrorjon Abdullayevich, Elamanova Vazira Ruyddinova, Akhmedov Sherzod Adkhamovich and Sobitkhodzhaeva Saida Ulmasovna
In order to conduct a comparative assessment of the effect of anticoagulant therapy on the coagulation profile and the outcome of coronavirus infection (COVID-19), were examined 372 patients with laboratory-confirmed COVID-19 (moderate-to-severe) in the Specialized Hospital from August to December 2020. The ratio of men and women was 1.6 / 1; the average age was 57.4 ± 6.77 years. In the course of the study, the antithrombotic and hemorrhagic effects of the oral anticoagulant Rivaroksaban Nobel (n = 122) in comparison with the parenteral anticoagulant Enoxaparin sodium (Clexane) (n = 250) were evaluated in a comparative aspect. Based on the risk of venous thromboembolism, standard treatment doses were used for oral Rivaroksaban Nobel 20 mg / day and Enoxaparin sodium (Clexane) is 8,000 IU (80 mg) once daily by subcutaneous (SC) injection. The study found that the incidence of both thromboembolic outcomes and bleeding events did not show statistically significant differences between the clinical and laboratory parameters of patients with COVID-19 with the recommended anticoagulant therapy Rivaroksaban NOBEL, compared with Enoxaparin sodium (Clexane). However, Enoxaparin sodium (Clexane) has shown more significant clinical efficacy compared to Rivaroksaban Nobel. On the other hand, during the use of Rivaroksaban Nobel, there were no significant differences in the incidence of acute respiratory distress syndrome and deaths compared with Enoxaparin sodium (Clexane). Thus, our study confirms the hypothesis about the safety and efficacy of the oral anticoagulant Rivaroksaban Nobel for the prevention of venous thromboembolism in hospitalized patients with moderate to severe COVID-19.
Keywords: Coronavirus infection (COVID-19), coagulation profile, anti-coagulant therapy, direct oral anticoagulants, unfractionated heparin, low-molecular-weight heparins, rivaroksaban, enoxaparin.
[Full Text Article]